CD163 and cancer: The high expression levels of ZIC2 and JUNB were positively correlated and linked to a poor outcomes in NPC patients, implying that ZIC2, JUNB, and CD163 could be utilized as prognostic markers for NPC and as therapeutic targets for cancer immunotherapy.